Corbus Pharmaceuticals Holdings Inc. said its only drug outperformed a placebo in a mid-stage study involving patients with a form of systemic sclerosis.

Gilead announced high cure rates across all types of hepatitis C in late-stage studies testing a triple drug combo; another experimental drug showed promise in reducing liver scarring in a mid-stage trial.

Swiss-based Roche (RHHBY) acquired San Francisco-based Adheron Therapeutics for up to $580 million today.   Adheron focuses on technology that disrupts cell adhesion, which has potential applications for a variety […]